Amicus Therapeutics Stock Forecast, Price & News

Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions

Is Amicus Therapeutics a buy right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 5 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Amicus Therapeutics stock.
View analyst ratings for Amicus Therapeutics or view top-rated stocks.

How has Amicus Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Amicus Therapeutics' stock was trading at $8.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, FOLD shares have increased by 29.8% and is now trading at $10.45.
View which stocks have been most impacted by COVID-19.

When is Amicus Therapeutics' next earnings date?

Amicus Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Amicus Therapeutics.

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) released its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.18) by $0.01. Amicus Therapeutics had a negative net margin of 81.17% and a negative trailing twelve-month return on equity of 84.62%. During the same quarter in the prior year, the business posted ($0.22) earnings per share.
View Amicus Therapeutics' earnings history.

What guidance has Amicus Therapeutics issued on next quarter's earnings?

Amicus Therapeutics issued an update on its FY 2021 earnings guidance on Tuesday, November, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $300 million-$315 million, compared to the consensus revenue estimate of $310.30 million.

What price target have analysts set for FOLD?

11 analysts have issued twelve-month price targets for Amicus Therapeutics' stock. Their forecasts range from $12.00 to $27.00. On average, they expect Amicus Therapeutics' share price to reach $16.56 in the next year. This suggests a possible upside of 58.4% from the stock's current price.
View analysts' price targets for Amicus Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Amicus Therapeutics' key executives?

Amicus Therapeutics' management team includes the following people:

• John Francis Crowley, Chairman & Chief Executive Officer
• Bradley Lewis Campbell, President, Chief Operating Officer & Director (LinkedIn Profile)
• Daphne E. Quimi, Chief Financial Officer
• Jill Weimer, Chief Science Officer
• Patrik S. Florencio, Senior VP, Global Chief Compliance & Risk Officer

What is John F. Crowley's approval rating as Amicus Therapeutics' CEO?

21 employees have rated Amicus Therapeutics CEO John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among Amicus Therapeutics' employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Amicus Therapeutics' key competitors?

Some companies that are related to Amicus Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Incyte (INCY), Exact Sciences (EXAS), Novavax (NVAX), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of FOLD's competitors.

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (9.53%), Wellington Management Group LLP (8.72%), BlackRock Inc. (7.35%), Morgan Stanley (4.19%), Deutsche Bank AG (2.67%) and Janus Henderson Group PLC (2.53%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends for Amicus Therapeutics.

Which major investors are selling Amicus Therapeutics stock?

FOLD stock was sold by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Deutsche Bank AG, BlackRock Inc., Two Sigma Advisers LP, Massachusetts Financial Services Co. MA, Voloridge Investment Management LLC, Longitude Cayman Ltd., and Primecap Management Co. CA. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Hung Do, John F Crowley, Margaret G Mcglynn, and Samantha Prout.
View insider buying and selling activity for Amicus Therapeutics or view top insider-selling stocks.

Which major investors are buying Amicus Therapeutics stock?

FOLD stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Perceptive Advisors LLC, Artal Group S.A., Janus Henderson Group PLC, Nordea Investment Management AB, BioImpact Capital LLC, Sphera Funds Management LTD., and Two Sigma Investments LP. Company insiders that have bought Amicus Therapeutics stock in the last two years include Burke W Whitman, and Lynn Dorsey Bleil.
View insider buying and selling activity for Amicus Therapeutics or or view top insider-buying stocks.

How do I buy shares of Amicus Therapeutics?

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amicus Therapeutics' stock price today?

One share of FOLD stock can currently be purchased for approximately $10.45.

How much money does Amicus Therapeutics make?

Amicus Therapeutics has a market capitalization of $2.91 billion and generates $260.89 million in revenue each year. The biopharmaceutical company earns $-276.85 million in net income (profit) each year or ($0.90) on an earnings per share basis.

How many employees does Amicus Therapeutics have?

Amicus Therapeutics employs 483 workers across the globe.

When was Amicus Therapeutics founded?

Amicus Therapeutics was founded in 2002.

What is Amicus Therapeutics' official website?

The official website for Amicus Therapeutics is www.amicusrx.com.

Where are Amicus Therapeutics' headquarters?

Amicus Therapeutics is headquartered at 1 Cedar Brook Drive, Cranbury NJ, 08512.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at (215) 921-7600, via email at [email protected], or via fax at 609-662-2001.